Case Report

Sequential pathological changes during malignant transformation of a craniopharyngioma: A case report and review of the literature

Tetsuya Negoto, Kiyohiko Sakata, Takachika Aoki, Kimihiko Orito, Shinji Nakashima¹, Masaru Hirohata, Yasuo Sugita¹, Motohiro Morioka

Departments of Neurosurgery, and Pathology, Kurume University School of Medicine, Fukuoka, Japan

E-mail: Tetsuya Negoto - emptydoughnut@gmail.com; Kiyohiko Sakata - kiyos@med.kurume-u.ac.jp; Takachika Aoki - takachi@med.kurume-u.ac.jp; Kimihiko Orito - orito_kimihiko@kurume-u.ac.jp; Shinji Nakashima - nakashima_shinji@med.kurume-u.ac.jp; Masaru Hirohata - hiroha@med.kurume-u.ac.jp; Yasuo Sugita - sugita_yasuo@med.kurume-u.ac.jp; *Motohiro Morioka - mmorioka@med.kurume-u.ac.jp

*Corresponding author

Received: 28 August 14 Accepted: 03 December 14 Published: 30 March 15

This article may be cited as: Negoto T, Sakata K, Aoki T, Orito K, Nakashima S, Hirohata M, et al. Sequential pathological changes during malignant transformation of a craniopharyngioma: A case report and review of the literature. Surg Neurol Int 2015;6:50.

Abstract

Background: Malignant transformation of craniopharyngiomas is quite rare, and the etiology of transformation remains unclear. The prognosis of malignantly transformed craniopharyngiomas is very poor.

Case Description: A 36-year-old male had five craniotomies, five transsphenoidal surgeries, and two radiation treatments until 31 years of age after diagnosis of craniopharyngioma at 12 years of age. All serial pathological findings indicated adamantinomatous craniopharyngioma including those of a surgery performed for tumor regrowth at 31 years of age. However, when the tumor recurred approximately 5 years later, the pathological findings showed squamous metaplasia. The patient received CyberKnife surgery, but the tumor rapidly regrew within 4 months. The tumor was resected with the cavernous sinus via a dual approach: Transcranial and transsphenoidal surgery with an extracranial-intracranial bypass using the radial artery. Pathologic examination of a surgical specimen showed that it consisted primarily of squamous cells; the lamina propria was collapsed, and the tumor cells had enlarged nuclei and clarification of the nucleolus. The tumor was ultimately diagnosed as malignant transformation of craniopharyngioma. After surgery, he received combination chemotherapy (docetaxel, cisplatin, and fluorouracil). The tumor has been well controlled for more than 12 months.

Conclusion: Serial pathological changes of the craniopharyngioma and a review of the 20 cases reported in the literature suggest that radiation of the squamous epithelial cell component of the craniopharyngioma led to malignant transformation via squamous metaplasia. We recommend aggressive surgical removal of craniopharyngiomas and avoidance of radiotherapy if possible.

Key Words: Craniopharyngioma, malignant transformation, squamous metaplasia, TPF chemotherapy
INTRODUCTION

Craniopharyngioma was first described in 1904 by Erdheim et al.[10] The term “craniopharyngioma”—introduced in 1932 by Cushing et al.[9]—refers to a benign epithelial tumor arising from the remnants of epithelial tissue in improperly formed pituitary glands or the craniopharyngeal duct remnants.[14,18] Craniopharyngioma accounts for 5–10% and 1.2–4.6% of adolescent and adult brain tumors, respectively.[5]

Malignant transformation of craniopharyngiomas is quite rare, with little information being available. It has been suggested that radiation and multiple surgeries are the inducing factors but the etiology of transformation remains unclear. We report a case of craniopharyngioma with malignant transformation and analyze the pathological transition.

CASE REPORT

The clinical course and corresponding figures are shown in Figure 1. A 36-year-old male had five craniotomies and five transsphenoidal surgeries between the ages of 12, when adamantinomatous craniopharyngioma was first diagnosed. He also received local irradiation at 15 years of age. When he was 31 years old, tumor regrowth occurred in the left cavernous sinus [Figure 2a]. We removed this lesion [Figure 2b], which appeared to be an adamantinomatous craniopharyngioma, and performed gamma-knife surgery (GKS) because of frequent cyst formations. When the patient was 36 years and 3 months of age, the tumor recurred in the cavernous sinus and surrounded the left optic nerve [Figure 2c]. Transsphenoidal biopsy was performed; the pathological findings showed squamous metaplasia, and CyberKnife surgery was performed on the residual lesion [Figure 2d]. However, the residual tumor regrew rapidly in the irradiated area during the next 4 months [Figure 2e and f], suggesting malignant transformation of the tumor. The patient was then readmitted to our department. Neurological findings at admission were blindness in his left eye and multiple complete nerve palsies of the oculomotor, trochlear, and abducens nerves on his left side. Because tumor invasion had spread into the cavernous sinus involving the carotid artery, we used a dual approach to resect the tumor, carotid artery, and cavernous sinus. Transcranial and transsphenoidal surgeries with an extracranial-intracranial (EC-IC) bypass using the radial artery. The postoperative course was uneventful, and the tumor was completely removed [Figure 3a-d].

Serial pathological changes are shown in Figures 4 and 5. In the specimen taken at 31 years of age, the tumor was covered with prickle cells, and a single layer of nonatypical basal cells and cholesterin crystals were present in the interstitial tissue. Internal layer of stellate cells in loose connective matrix was found [Figure 4a and b]. Similar findings had been reported in all serial pathologic examinations before 31 years of age, and the tumor was diagnosed as an adamantinomatous craniopharyngioma. The specimen taken at 36 years and 3 months of age showed densely packed squamous cells and stratification of basal cells with an atypical appearance characteristic of squamous metaplasia. The features of adamantinomatous craniopharyngioma were no longer apparent [Figure 4c, d].

A specimen from the transcranial and transsphenoidal dual surgeries consisted chiefly of squamous cells [Figure 5]. The lamina propria was collapsed, and infiltration of atypical cells was observed in interstitial tissue. Tumor cells had enlarged nuclei and clarification of the nucleolus. Parakeratosis and intercellular bridges were also present in the tissue, which resembled...
Squamous cell carcinoma (SCC). As shown in immunohistochemistry, the abundance of p40 (a specific marker of squamous cells) and p53 (the indicator of malignancy) progressively increased between the ages of 31 and 36 years and 9 months [Figure 6]. On the basis of these findings, the case was ultimately diagnosed as malignant transformation of craniopharyngioma.

After the transcranial and transsphenoidal dual surgeries, the patient received chemotherapy consisting of docetaxel (75 mg per body surface squared), cisplatin (100 mg per body surface squared), and fluorouracil (1000 mg per body surface squared) (TPF chemotherapy). The tumor has been well controlled for more than 12 months after surgery.

**DISCUSSION**

A craniopharyngioma is typically a pathologically benign tumor with no malignant features; malignant craniopharyngioma is quite rare. According to the World Health Organization (WHO) classification of tumors of the central nervous system published in 2007, “malignant transformation of craniopharyngioma to squamous carcinoma after irradiation is exceptional.” To our knowledge, only 20 craniopharyngioma cases with malignant features (or transformation) have been reported [Table 1] [1,2,4,15-17,22,24,26,27,30,32,33,35]. Excluding four de novo cases, the male to female ratio is 11:9, the mean age of onset is 21.3 years (range, 6–66 years), and the mean duration from the first operation to malignant transformation is 9 years (range, 3–24 years). Fifteen of the 20 cases (75%) had a history of radiation therapy,
which suggests that radiation may be a strong inducer of malignant transformation. In our case, the patient had received two previous radiation treatments, and malignant changes occurred 4 months after CyberKnife surgery. However, de novo malignant craniopharyngiomas can occur in the absence of prior radiation, then the etiology of the transformation remains obscure. There are no clear definitions of malignant craniopharyngiomas in previous reports. As summarized by Cao et al.,[13] the characteristics of malignant craniopharyngioma include a high proliferative index and high mitotic activity and histologic features such as destruction of the basement membrane, infiltrative growth, and coagulative necrosis. Because the present case included malignant histological findings such as large nuclei, clarification of the nucleolus, parakeratosis, and intercellular bridges, it was diagnosed as malignant craniopharyngioma. For management of suprasellar tumors with malignancy, some infrequent patterns of tumor should be considered. Chang et al.[7] reported a case of a recurrent olfactory neuroblastoma invading the brain base, in which focal components of craniopharyngioma were found. They suggest that this is an example of a neoplasm with a single origin that developed histological heterogeneity during progression rather than two distinct neoplasms developing concurrently. Naresh et al.[21] reported similar tumor and considered it as a sinonasal teratocarcinosarcoma. Nishioka et al.[23] described an odontogenic-like neoplasia as a malignant odontogenic tumor without morphological evidence of craniopharyngioma. Adamantinomatous craniopharyngioma histologically resembles some odontogenic tumors but consistently shows odontogenic epithelial differentiation in immunohistochemistry.[22,29] Our case showed the same pathological findings of benign adamantinomatous craniopharyngioma during 20 years without other pathological finding. Therefore, the tumor in our case is not considered to be a teratocarcinosarcoma or an odontogenic tumor.

Pathologically, two principal types of craniopharyngioma are recognized, adamantinomatous and squamous papillary.[11] Most of the reported cases with malignant changes in which the initial diagnosis was adamantinomatous craniopharyngioma, showed malignant squamous epithelial cell components, such as squamous carcinoma cells [Table 1]. Likewise, in our case, the features of adamantinomatous craniopharyngioma disappeared and squamous cell components materialized during malignant transformation. Our case showed squamous metaplasia with cells expressing p40, a specific

| Author, year | Sex | Age (presentation) | Time to MT (year) | Radiation Therapy after MT | Outcome/duration | Histology (authors' description) (at first/at MT) |
|--------------|-----|--------------------|-------------------|---------------------------|-----------------|-----------------------------------------------|
| Akachi et al. 1987 | F | 7 | 3 | + | Surgery(2), RT | Dead/8 m after MT | AC/MT |
| Nelson et al. 1988 | F | 14 | 3 | + | Surgery | Dead/11 w after surgery | AC/MC |
| Suzuki et al. 1989 | M | 3 | 8 | + | RT, V P shunt | Dead/2m after MT | AC/SCC |
| Suzuki et al. 1989 | M | 9 | 5 | + | Surgery | Dead/3 m after MT | AC/SCC |
| Virik et al. 1999 | M | 24 | 10 | + | Surgery, CT(carboblatin, etoposide), RT | Dead/10 m after MT | AC/UET |
| Kristopatis et al. 2000 | F | 27 | 15 | + | Surgery, CT (pacitaxel, carboplatin) | Alive/6m after MT | AC/SCC |
| Sakai et al. 2004 | M | 3 | 14 | + | Surgery(5), stereotactic radiosurgery(2) | Dead/3 y after MT | y/MT with PP |
| Plowman et al. 2004 | F | 6 | 15 | + | Surgery, CT(cisplatin, etoposide) | Dead/6m after MT | AC/MT without SF |
| Yue et al. 2006 | M | 17 | 0 | - | Surgery | Dead/6 w after surgery | None |
| Rodriguez et al. 2007 | M | 31 | 0 | - | Surgery, shunt | Dead/2 m after MT | AC/MEC |
| Rodriguez et al. 2007 | F | 58 | 5 | + | Surgery | Dead/6 w after surgery | None |
| Boongird. et al. 2008 | F | 46 | 0 | - | Surgery | Dead/6 m after MT | None |
| Ishida et al., 2010 | M | 6 | 5 | + | Surgery, CT (cydophosphamide, cisplatin, etoposide) | Alive/10 m after MT | AC/MT |
| Aquilina et al., 2010 | M | 4 | 8 | + | Surgery(2), CT (carboblatin, cetuximab) | Dead/6 m after MT | y/SCC |
| Aquilina et al., 2010 | F | 6 | 7 | + | Surgery, CT(pacitaxel, carboplatin), RT | Alive/y after MT | AC/SCC |
| Uijfuku et al. 2010 | M | 32 | 10 | + | Surgery (2) | Dead/43 d after surgery | AC/SCC |
| Launola et al. 2011 | F | 66 | 0 | - | RT | Dead/15 m after surgery | None |
| Gao et al. 2011 | F | 41 | 4 | - | Surgery | Dead/3 m Mfrer cuergy | MIX/ABC |
| Present case | M | 12 | 24 | + | Surgery | Alive/12 m after surgery | AC/MT |

ABC: Ameloblastic carcinoma; AC: adamantinomatous craniopharyngioma; MC: Malignant craniopharyngioma; MEC: Myoepithelial craniopharyngioma; MIX: Mixed type craniopharyngioma; MT: Malignant transformation; OGC: Odontogenic ghost cell carcinoma; PC: Papillary craniopharyngioma; PP: Pleomorphic pattern; RT: Radiation therapy; SCC: Squamous cell carcinoma; SF: Squamous features; UET: Undifferentiated epithelial tumor; d: Day; m: Month; y: Year; 1: De novo tumor

Table 1: Summary of the reported 20 cases of malignant transformation of craniopharyngioma
squamous cell marker.\textsuperscript{[3]} An important issue concerns the origin of the malignantly transformed epithelial cells. Yamada et al.\textsuperscript{[14]} explained the histogenesis of craniopharyngioma as follows: The anterior wall of Rathke’s pouch epithelium fails to evolve into the adenohypophysis and transforms into either enamel organs (adamantinomatous) or oral mucosa composed of nonkeratinized squamous epithelium (papillary squamous). The WHO classification of tumors of the central nervous system published in 2007\textsuperscript{[19]} states that adamantinomatous craniopharyngioma is characterized by squamous epithelium disposed in cords, and thus contains “peripheral palisading epithelium,” whereas squamous papillary craniopharyngioma consists of “squamous and well-differentiated non-keratinizing epithelium.”\textsuperscript{[28]} Both types may transform to malignant SCC-like tumors.

Possible mechanisms of malignant tumorigenesis in our case are as follows [Figure 7]: (i) The peripheral palisading epithelium of the adamantinomatous craniopharyngioma undergoes transformation; (ii) the squamous cells of a coexisting papillary squamous craniopharyngioma (or a mixed type tumor) undergo transformation; (iii) neighboring normal epithelial cells undergo transformation; and (iv) the adamantinomatous craniopharyngioma hosts a distant metastasis (the tumor to tumor phenomenon). The first two hypotheses fit our findings, and the first is the most plausible. There was no pathological evidence of squamous papillary craniopharyngioma during the long clinical course of the tumor nor were p40-positive cells observed before squamous metaplasia arose. In addition, the possibility of collateral damage from radiation therapy (e.g., a radiation-induced malignant tumor) must be considered.\textsuperscript{[30,31]} Cahan et al.\textsuperscript{[6]} and Menon et al.\textsuperscript{[20]} found that the latency period necessary for malignant transformation was more than 5 years after radiotherapy. In our case, the patient received GKS at 31 years of age and local irradiation at 15 years of age; both treatments are potential triggers of transformation. An otherwise benign craniopharyngioma may occasionally serve as the “recipient” in rare tumor-to-tumor metastasis situations [Figure 7d]. Fraggetta et al.\textsuperscript{[12]} reported a case with metastasis of pulmonary adenocarcinoma to the craniopharyngioma. Although we did not find any other malignant tumors in our case, we must always consider the tumor-to-tumor phenomenon.

The prognosis of malignantly transformed craniopharyngioma is very poor [Table 1]. After diagnosis of malignant transformation, surgical resection, additional radiation, and chemotherapy have been administered. Although none of these treatments individually resulted in long-term survival, the combination of surgical resection and chemotherapy is now considered the best treatment. All chemotherapies for malignant craniopharyngioma included platinum, and three of six (50\%) patients receiving combination therapy are still alive at present. For these reasons, we administered TPF chemotherapy\textsuperscript{[25]} to our patient, but its long-term effect is unknown.

It is unclear whether radical surgery is better than other types of surgery for resection of craniopharyngiomas. Although mortality and morbidity rates after radical surgery for tumors surrounding the cavernous sinus are relatively high, Couldwell et al.\textsuperscript{[8]} recommend radical resection of such tumors in the following situations: (i) Benign tumors recur despite all reasonable medical and radiation therapies, including stereotactic radiosurgery and fractionated radiation; (ii) as a salvage therapy for malignant tumors for which no other therapy is reasonable; and (iii) the patient is in an acceptable neurologic and general physiologic condition for attempts to extend survival. Because our patient had complete paresis of all nerves related to the cavernous sinus, we performed a radical tumor resection including the cavernous sinus using both transcranial and transphenoidal techniques and an EC-IC bypass. The surgery completely removed the tumor, and there has been no tumor regrowth. It is now 12 months after surgery, and our patient has not manifested any new neurological deficits. The management of malignant transformation of craniopharyngioma is currently unclear and controversial in terms of how best to remove the tumor and which type of chemotherapy is the most effective. Because radiation may be a strong inducer of malignant transformation, we suggest that radical removal of the craniopharyngioma and avoidance of radiation therapy may be the best options.

![Figure 7: Diagram of the possible mechanisms of craniopharyngioma transformation. (a) The peripheral palisading epithelium of an adamantinomatous craniopharyngioma (aCP) undergoes transformation. (b) The squamous cells of a coexisting papillary squamous craniopharyngioma (pCP) or a mixed-type tumor undergo transformation. (c) Neighboring normal epithelial cells undergo transformation. (d) A distant metastasis invades an aCP.](image-url)
ACKNOWLEDGMENTS

The authors thank Ms. Keiko Suematsu for technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Sports, Science, and Culture of Japan. There are no conflicts of interest. The authors would like to thank Editage (www.editage.jp) for English language editing.

REFERENCES

1. Akachi K, Takahashi H, Ishijima B, Nakamura Y, Oda M, Takizawa T. et al. Malignant changes in a craniopharyngioma. No Shinkei Geka 1987;15:843-8.

2. Aquilina K, Merchant TE, Rodriguez-Galindo C, Ellison DW, Sanford RA, Boop FA. Malignant transformation of irradiated craniopharyngioma in children: Report of 2 cases. J Neurosurg Pediatr 2010;5:155-61.

3. Bishop JA, Teruya Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25:405-15.

4. Boogird A, Laothamatas J, Larbcharoensub N, Phudichareonrat S. Malignant craniopharyngioma; Case report and review of the literature. Neuropathology 2009;29:591-6.

5. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. Descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89:547-51.

6. Cahan WG, Woodard HQ. Sarcoma arising in irradiated bone; Report of 11 cases. Cancer 1948;1:3-29.

7. Chang KC, Jin YT, Chen RM, Su LJ. Mixed olfactory neuroblastoma and craniopharyngioma: An unusual pathological finding. Histopathology 1997;30:378-82.

8. Couldwell WT, MacDonald JD, Taussky P. Complete Resection of the cavernous sinus-indications and technique. World Neurosurg 2014;82:1264-1270.

9. Cushing H. The craniopharyngiomas. In: Intracranial tumors. Notes upon a series of two thousand verified cases with surgical mortality percentages pertaining thereto. Springfield, Illinois; 1932. p. 93-8.

10. Erdheim J. Ueber hypophysengangsgeschwulste und hirncholesterome. Akad Wiss Wien 1904;113:537-726.

11. Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Suárez C. et al. Craniopharyngioma: A pathologic, clinical, and surgical review. Head Neck 2012;34:1036-44.

12. Fraggetta F, Galia A, Grasso G, D’Arrigo C, Cristaudo C, Giangaspero F. Pulmonary adenocarcinoma metastatic to pituitary craniopharyngioma. J Clin Pathol 2000;53:946-7.

13. Gao S, Shi X, Wang Y, Qian H, Liu C. Malignant transformation of craniopharyngioma: Case report and review of the literature. J Neurooncol 2011;103:719-25.

14. Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis 2007;10:2-18.

15. Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, et al. Malignant transformation in craniopharyngioma after radiation therapy: A case report and review of the literature. Clin Neuropathol 2010;29:2-8.

16. Kristopatis T, Thomas C, Petruzelli GJ, Lee JM. Malignant craniopharyngioma. Arch Pathol Lab Med 2000;124:1356-60.

17. Lauriola L, Doglietto F, Novello M, Signorelli F, Montano N, Pallini R, et al. De novo malignant craniopharyngioma: Case report and literature review. J Neurooncol 2011;103:381-6.

18. Lindholm J, Nielsen EH. Craniopharyngioma: Historical notes. Pituitary 2009;12:352-9.

19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.

20. Menon GI, Nair S, Rajesh BJ, Rao BR, Radhakrishnan VV. Malignant astrocytoma following radiotherapy for craniopharyngioma. J Cancer Res Ther 2007;3:50-2.

21. Naresh KN, Pai SA. Foci resembling olfactory neuroblastoma and craniopharyngioma are seen in sinonasal teratocarcinosarcomas. Histopathology 1998;32:84.

22. Nelson GA, Bastian FO, Schlitt M, White RL. Malignant transformation in craniopharyngioma. Neurosurgery 1988;22:427-9.

23. Nishioka H, Shibuya M, Iawaha I, Ikeda Y. Primary suprasellar malignant tumor with odontogenic features: Case report. J Neurosurg 2009;65:E380-2.

24. Plowman PN, Besser GM, Shipley J, Sommergil B, Geddes J, Afshar F. Dramatic response of malignant craniopharyngioma to cisplatin-based chemotherapy. Should craniopharyngioma be considered as a suprasellar ‘germ cell’ tumour? Br J Neurosurg 2004;18:500-5.

25. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Wingquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.

26. Rodriguez FD, Scheithauer BW, Tsuonoda S, Kovacs K, Vidal S, Piepgs DG. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 2007;31:1020-8.

27. Sakai K, Tanaka Y, Hongo K, Tada T, Shigeta H, Kobayashi S. Treatment of craniopharyngiomas in children. No Shinkei Geka 2004;32:345-53.

28. Sarah JL, Olfar A. Pathology and pathogenesis of craniopharyngioma. Pituitary 2004;7:509-17.

29. Sekine S, Takata T, Shibata T, Mori M, Morishita Y, Noguchi M. Treatment of craniopharyngioma in children. No Shinkei Geka 2004;32:121-6.

30. Suzuki F, Konuma I, Matsumoto M, Aoki M, Hayakawa I. Craniopharyngioma with malignant transformation—A report of two cases. Gan No Rinsho 1989;35:723-8.

31. Tanaka S, Konuma I, Matsumoto M, Aoki M, Hayakawa I. Craniopharyngioma with malignant transformation—A report of two cases. Clin Neuropathol 2010;29:2-8.

32. Ufujuku K, Matsuo T, Takeshita T, Hayashi Y, Hayashi K, Kitagawa N, et al. Malignant transformation of craniopharyngioma associated with moyamoya syndrome. Neurol Med Chir (Tokyo) 2010;50:599-603.

33. Virik K, Turner J, Garrick R, Sheehy JP. Malignant transformation of craniopharyngioma. J Clin Neurosci 1999;6:527-30.

34. Yamada H, Haratake J, Narasaki T, Oda T, Embrtonal Craniopharyngioma. Case report of the morphogenesis of a craniopharyngioma. Cancer 1995;75:2971-7.

35. Yue Y, Da JP. Malignant transformation of craniopharyngioma: A case report. Zhonghua Bing Li Xue Za Zhi 2006;35:439.

http://www.surgicalneurologyint.com/content/6/1/50